Drug General Information |
Drug ID |
D00MPA
|
Former ID |
DNC008480
|
Drug Name |
6-(furan-2-yl)-9H-purin-2-amine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C9H7N5O
|
Canonical SMILES |
C1=COC(=C1)C2=C3C(=NC(=N2)N)N=CN3
|
InChI |
1S/C9H7N5O/c10-9-13-6(5-2-1-3-15-5)7-8(14-9)12-4-11-7/h1-4H,(H3,10,11,12,13,14)
|
InChIKey |
JZSMPSCWNAYWOI-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Vascular smooth muscle contraction
|
Parkinson's disease
|
Alcoholismhsa04022:cGMP-PKG signaling pathway
|
Sphingolipid signaling pathway
|
Morphine addiction
|
NetPath Pathway
|
TCR Signaling Pathway
|
RANKL Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Reactome
|
NGF-independant TRKA activation
|
Adenosine P1 receptors
|
G alpha (s) signalling events
|
Surfactant metabolismR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Nucleotide GPCRs
|
Monoamine Transport
|
GPCRs, Class A Rhodopsin-like
|
NGF signalling via TRKA from the plasma membrane
|
GPCR ligand binding
|
GPCR downstream signaling
|
GPCRs, OtherWP80:Nucleotide GPCRs
|
References |
REF 1 | J Med Chem. 2009 Jan 8;52(1):33-47.Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. |